Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 5/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8027766 | 0.89 | RNASE1 (0.41) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL6232615 | 0.88 | RNASE1 (0.42) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL3290516 | 0.88 | RNASE1 (0.43) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL8027668 | 0.86 | RNASE1 (0.41) | RNASE1TK1TYMSTK2 | |
| SCHEMBL8034055 | 0.86 | RNASE1 (0.40) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL6830771 | 0.86 | RNASE1 (0.51) | RNASE1TK1TYMSTYMP | |
| SCHEMBL6827418 | 0.85 | RNASE1 (0.53) | RNASE1TK1TYMSTK2 | |
| SCHEMBL6323173 | 0.85 | RNASE1 (0.51) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL6316914 | 0.85 | RNASE1 (0.42) | RNASE1TK1TK2 | |
| SCHEMBL24217748 | 0.85 | RNASE1 (0.45) | RNASE1TK1TYMSTK2TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967247-B2 | Deprotection of phosphorus in oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20040024194-A1 | Deprotection of phosphorus in oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024194-A1 | Deprotection of phosphorus in oligonucleotide synthesis | OR51E2, PNKP, RNGTT | RNASE1 400/4885TK1 125/4885TYMS 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.